Ebola

Conducting Clinical Trials During COVID-19: Lessons for the Next Pandemic, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, April 22, 2021
Medical specialties, Sexually transmitted diseases and infections, Zoonoses, Clinical medicine, Zika virus, Vaccination, Vaccine, Virology, Zika fever, Ebola

b'TORONTO, April 22, 2021 /PRNewswire-PRWeb/ -- The coronavirus is not the first infectious disease that has forced clinical trials to adapt.

Key Points: 
  • b'TORONTO, April 22, 2021 /PRNewswire-PRWeb/ -- The coronavirus is not the first infectious disease that has forced clinical trials to adapt.
  • Zika, Ebola and other diseases called for the world to adjust and collaborate global research efforts.
  • The global research community have already discovered and developed several tests and vaccines in record time through collaboration.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.\nAyesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected]\n'

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021

Retrieved on: 
Monday, April 19, 2021
Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Ebola, Chemical compounds, COVID-19, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, XC2, Antiviral drug, Infection

By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Key Points: 
  • By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan\xc2\xae / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.
  • For more information, visit www.AppiliTherapeutics.com .\nBloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.

FLIR Wins DARPA Contract Worth Up to $20.5M to Develop Revolutionary New Protective Fabrics for Chem-Bio Defense

Retrieved on: 
Monday, April 12, 2021
Other Health, Research, Other Defense, Contracts, Technology, Defense, Security, Science, Homeland security, Other Technology, Health, Public policy, Government, Clothing, Protective gear, Medical specialties, Articles, Environmental social science, Industrial hygiene, Occupational safety and health, Working conditions, Personal protective equipment, Glove, Eye protection, Ebola

The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more.

Key Points: 
  • The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more.
  • FLIR received $11.2 million in initial funding for the potential five-year effort worth up to $20.5 million, including options.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210412005140/en/\nThe Personalized Protective Biosystems (PPB) program will create fabrics with built-in ability to fight chemical and biological agents, from VX to chlorine gas to Ebola virus.
  • The revolutionary fabrics being developed by FLIR Systems will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical and healthcare workers, and more.

CDC Foundation Supports Guinea and the Democratic Republic of the Congo to Take on Latest Ebola Outbreaks in Both Nations

Retrieved on: 
Monday, March 22, 2021
Medical specialties, Infectious diseases, Continents, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Zoonoses, Bat virome, Ebola, Democratic Republic of the Congo

At the same time, another Ebola outbreak is continuing in the Democratic Republic of the Congo (DRC).

Key Points: 
  • At the same time, another Ebola outbreak is continuing in the Democratic Republic of the Congo (DRC).
  • "Right now, it is critical to take steps to strengthen the responses in Guinea and DRC," said Judy Monroe, MD, president and CEO of the CDC Foundation.
  • In Guinea, the CDC Foundation is assisting with an urgent and timely request to support Agence Nationale de Scurit Sanitaire (ANSS) which is part of the Ministry of Health.
  • The CDC Foundation managed hundreds of CDC-led programs in the United States and in more than 140 countries last year.

Ebola, Still a Threat to Global Health, Says AHF

Retrieved on: 
Monday, March 15, 2021
AIDS, Public policy, Government, Health, Public policy, Infectious diseases, General Health, Pharmaceutical, Health law, World Health Organization, Medical specialties, Health, Emergency management, Public Health Emergency of International Concern, Infectious diseases, West African Ebola virus epidemic, Ebola

The World Health Organization (WHO) must be ready to declare a Public Health Emergency of International Concern (PHEIC) if the outbreak starts to accelerate.

Key Points: 
  • The World Health Organization (WHO) must be ready to declare a Public Health Emergency of International Concern (PHEIC) if the outbreak starts to accelerate.
  • During the prior outbreaks 2,543 people died of Ebola in Guinea and 2,299 in the DRC.
  • Previously, Ebola-related PHEIC declarations were promulgated during the 2013-2016 outbreak in West Africa , and the 2018-2020 Kivu outbreak in the DRC.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005705/en/

Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today

Retrieved on: 
Wednesday, February 24, 2021
Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Chemical compounds, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Infection, Biocom Global, Appili Therapeutics

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Global Disease Expert Available to Comment on New Ebola Outbreak in Guinea

Retrieved on: 
Wednesday, February 17, 2021
Medical specialties, West African Ebola virus epidemic, Infectious diseases, Ebola, Zoonoses, Biological weapons, Tropical diseases, Cultural effects of the Western African Ebola virus epidemic, Responses to the West African Ebola virus epidemic

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 /PRNewswire/ -- Richard Reithinger , Ph.D., Vice President of Global Health at RTI International (RTI), a nonprofit research institute, is available to comment on the new Ebola outbreak in Guinea, which has been proclaimed an epidemic.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 /PRNewswire/ -- Richard Reithinger , Ph.D., Vice President of Global Health at RTI International (RTI), a nonprofit research institute, is available to comment on the new Ebola outbreak in Guinea, which has been proclaimed an epidemic.
  • Dr. Reithinger is an infectious disease expert with extensive experience managing health programs around the globe.
  • Infectious disease SME Dr. Richard Reithinger can comment on new Ebola outbreak in Guinea, now considered an epidemic.
  • During the Ebola outbreak in Guinea from 2014-2016, RTI aided the Guinean government and supported USAID's StopPalu project to mitigate the impact of Ebola on malaria treatment programs.

Antler Gold Appoints Christopher Drysdale as Vice President and Provides Exploration Update on Its Erongo Gold Project, Central Namibia

Retrieved on: 
Tuesday, February 16, 2021
Medical specialties, Continents, Infectious diseases, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Zoonoses, Ebola, Antler, EVD, GUINEA

Christopher was previously Antler's Manager of Corporate Development and was directly responsible for Antler having the opportunity to secure the Erongo Project.

Key Points: 
  • Christopher was previously Antler's Manager of Corporate Development and was directly responsible for Antler having the opportunity to secure the Erongo Project.
  • Antler also provides an update on exploration currently underway on the project.
  • Antler Gold Inc. (TSXV: ANTL) is a Canadian company, focused on the acquisition and exploration of gold projects in Namibia.
  • For further information, please contact Daniel Whittaker, President and CEO of Antler Gold Inc., at (902) 488-4700.

Ebola virus disease in Nzérékoré – Guinea

Retrieved on: 
Tuesday, February 16, 2021
Medical specialties, Medicine, Health sciences, Zoonoses, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Ebola, Zaire ebolavirus, Virus, EVD, Western African Ebola virus epidemic

On 14 February 2021, an Ebola virus disease (EVD) outbreak was declared in the rural area of Gouk in NZerekore region, Guinea, by national health authorities.

Key Points: 
  • On 14 February 2021, an Ebola virus disease (EVD) outbreak was declared in the rural area of Gouk in NZerekore region, Guinea, by national health authorities.
  • Samples from the confirmed cases have been sent to the Institut Pasteur in Senegal for full genome sequencing in order to identify the strain of the Ebola virus.
  • Significant developments have been made in the prevention of Ebola virus disease, with two vaccines now licensed for use in several countries.
  • For other EU/EEA citizens living in or travelling through Guinea, the likelihood of exposure is very low, as is the likelihood of introduction and further spread of the Ebola virus within the EU/EEA.

Outbreak of Ebola virus disease in North Kivu – Democratic Republic of the Congo – 2021

Retrieved on: 
Tuesday, February 16, 2021
Medical specialties, Medicine, Infectious diseases, Biological weapons, Tropical diseases, Zoonoses, West African Ebola virus epidemic, Ebola, Zaire ebolavirus, Democratic Republic of the Congo Ebola virus outbreak, Western African Ebola virus epidemic

On 7 February 2021, the Minister of Health of the Democratic Republic of the Congo (DRC) declared an outbreak of Ebola virus disease after a laboratory-confirmed case was detected.

Key Points: 
  • On 7 February 2021, the Minister of Health of the Democratic Republic of the Congo (DRC) declared an outbreak of Ebola virus disease after a laboratory-confirmed case was detected.
  • This current outbreak constitutes the 12th outbreak of Ebola virus disease in the DRC.
  • Her husband was an Ebola virus disease survivor whose biological samples had tested negative twice since 28 September 2020; she died on 4 February 2021.
  • In addition, as the virus is present in the animal reservoir in many parts of the country, Ebola virus disease outbreaks are recurrent.